|
|
|
| Comparison on Efficacy of Docetaxel, Irinotidine and Tiggio in Patients with Advanced Gastric Cancer |
| WANG Wenming, DUAN Aixiong, JIANG Qi'an, et al |
| Anqing Hospital Affiliated to Anhui Medical University, Anhui Anqing 246003, China |
|
|
|
|
Abstract Objective: To investigate the clinical efficacy and safety of docetaxel combined with irinotecan and irinotecan combined with teggio in patients with advanced gastric cancer. Methods: 35 patients with advanced gastric cancer receiving chemotherapy with docetaxel combined with tiggio in the department of oncology of our hospital between September 2013 and April 2018 were selected as the experimental group, and 25 patients receiving irinotecan combined with tiggio as the control group. The disease control rate and toxicity reaction after chemotherapy were compared between the two groups. The clinical value of docetaxel and irinotidine combined with teggio in patients with advanced gastric cancer were evaluated. Results: The tumor remission rate and control rate of the experimental group were 34.29% and 71.43%, respectively, while those of the control group were 36% and 72%. The difference between the two groups was not statistically significant (χ2=0.019, 0.002, P>0.05). After chemotherapy toxicity of two groups of reactions including leukopenia, thrombocytopenia, nausea and vomiting, hair loss, neurotoxicity, and extremities syndrome, etc., and all kinds of reaction is given priority to with 0 ~ Ⅱ degrees, differences were not statistically significant (P>0.05). Conclusion: Docetaxel combined with tegeor and irinotecan combined with tegeor can effectively control the development speed of cancer patients, reduce the occurrence of toxic reactions, and both of them have the same effect, and the patients with toxic reactions can tolerate, which is worthy of clinical application.
|
|
|
|
|
|
[1] Koca D , Dogan E , Yardim H , et al. A modified DCF regimen as primary treatment for patients with metastatic gastric cancer.[J]. Journal of Buon, 2013, 18(2):377~384.
[2] 彭良群,杨巍,张占东,等.21例新辅助化疗后病理完全缓解胃癌患者临床特征及预后分析[J].中华胃肠外科杂志,2017,20(10):1168~1173.
[3] 戴兴,吴朝阳.多西他赛、奥沙利铂、替吉奥联合治疗127例晚期胃癌患者的临床疗效[J].实用癌症杂志,2018(3):443~446,457.
[4] 武新华.多西他赛联合奥沙利铂和替吉奥一线治疗晚期胃癌临床效果观察[J].中外医学研究,2019,17(7):46~47.
[5] 谢文健,闵江,钱昆,等.多西他赛或伊立替康联合奥沙利铂及替吉奥治疗晚期胃癌的临床疗效及安全性分析[J].重庆医学,2017,46(19):2644~2648.
[6] 杨洋,刘丽.《早期胃癌内镜下规范化切除的专家共识意见(2018)》解读[J].河北医科大学学报,2019,40(6):623~628.
[7] 高莉莉,朱海峰,周九三,等.联合应用多西他赛、奥沙利铂和替吉奥新辅助化疗治疗进展期胃癌的疗效[J].江苏医药,2017,43(6):393~395.
[8] 张雄,李胜,高平,等.多西他赛联合铂类药物及替吉奥化疗方案对晚期胃癌病灶中癌细胞生长的影响[J].海南医学院学报,2017,23(12):1697~1700,1704.
[9] 刘沙.多西他赛联合卡培他滨或替吉奥治疗老年进展期胃癌的效果观察[J].中国综合临床,2017,33(6):519~523.
[10] 刘浩.多西他赛联合奥沙利铂和替吉奥一线治疗晚期胃癌的临床疗效和毒副作用观察[J].现代诊断与治疗,2018,29(8):1234~1235.
[11] Kubo T , Kawano Y , Himuro N , et al. BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer[J]. Gastric Cancer, 2016, 19(3):827~838.
[12] 张文丽.探讨多西他赛联合奥沙利铂和替吉奥胶囊方案治疗晚期胃癌的临床疗效及不良反应[J].当代医学,2019,25(2):97~99. |
|
|
|
2020, Vol. 26 
